Comply with new prices of 137 anti-cancer drugs or face action, says regulator

NEW DELHI The National Pharmaceutical Pricing Authority (NPPA) has warned of penal action against those failing to comply with the revised prices of 137 non-scheduled anti-cancer drugs The authority, which functions under the Department of Pharmaceuticals, has asked State drug controllers (SDCs) to strictly monitor the prices and submit their action taken reports by November 16, according to an official release on Friday (November 13, 2026).

The revised prices for the 137 anti-cancer drugs came into effect on November 9, 2026, following a gazette order issued on October 17, 2026.

The order capped the trade margin on these medicines at 30%.

Based on submissions received from pharmaceutical companies up to November 11, the latest revised price lists have been uploaded on the NPPA website as well as the Pharma Sahi Daam app and portal, the Chemicals and Fertilizers Ministry said.

All manufacturers, stockists, dealers, retailers, hospitals, and medical institutions have been directed to comply with the revised prices and prominently display the updated price lists at their premises and on their websites.

The SDCs have been instructed to strictly monitor compliance across the supply chain and healthcare facilities to ensure that the benefits of the revised maximum retail prices (MRPs) are passed on to patients.

Any violation of the directive may attract overcharging proceedings under the provisions of the DPCO, 2013, the release noted.

Complaints regarding overcharging, shortage, or non-availability of medicines can be reported through the Pharma Sahi Daam app or portal, the NPPA helpline (1800-111-255), or via email at monitoring-nppa@gov.in, it added.